3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
23
Phase 2
3
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
4
Other hematologic neoplasm
3
Lymphoid
2
Breast
2
Tumor-Agnostic
1
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
1
Lung Neoplasms
1
Colonic Neoplasms
1
Interventions
Fluorouracil
308
Oxaliplatin
259
Leucovorin
233
Capecitabine
198
Irinotecan
145
Gemcitabine
127
Cisplatin
126
Bevacizumab
119
Radiotherapy
72
Paclitaxel
63
Folfox protocol
56
Cetuximab
56
Drug Therapy
46
Sorafenib
45
Docetaxel
41
S 1 (combination)
40
Chemotherapy, Adjuvant
38
Neoadjuvant Therapy
37
pembrolizumab
36
Surgical Procedures, Operative
27
130-nm albumin-bound paclitaxel
27
regorafenib
25
lenvatinib
24
XELOX
24
Panitumumab
24
Radiation
23
Nivolumab
22
trifluridine tipiracil drug combination
21
atezolizumab
21
Carboplatin
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Practice Guidelines as Topic
×
Gastrointestinal
×
Clear all
NCT06563388
2026-02-04
ID-COMET
Roswell Park Cancer Institute
Phase 3
Recruiting
800 enrolled